KBC Group NV Sells 24,404 Shares of Royalty Pharma PLC $RPRX

KBC Group NV lessened its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 13.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 163,561 shares of the biopharmaceutical company’s stock after selling 24,404 shares during the period. KBC Group NV’s holdings in Royalty Pharma were worth $6,320,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of RPRX. Smartleaf Asset Management LLC lifted its stake in shares of Royalty Pharma by 868.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 790 shares during the last quarter. Financial Consulate Inc. bought a new stake in shares of Royalty Pharma in the 3rd quarter valued at about $35,000. Larson Financial Group LLC lifted its stake in shares of Royalty Pharma by 31.9% in the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 306 shares during the last quarter. Richardson Financial Services Inc. bought a new stake in shares of Royalty Pharma in the 3rd quarter valued at about $54,000. Finally, Farther Finance Advisors LLC lifted its stake in shares of Royalty Pharma by 44.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,060 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 632 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.

Insider Buying and Selling

In other Royalty Pharma news, EVP Marshall Urist sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $41.09, for a total transaction of $821,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Terrance P. Coyne sold 114,954 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $42.84, for a total value of $4,924,629.36. Following the completion of the transaction, the chief financial officer directly owned 23,972 shares of the company’s stock, valued at $1,026,960.48. This represents a 82.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 457,496 shares of company stock valued at $19,618,025 in the last ninety days. 18.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. TD Cowen reissued a “buy” rating on shares of Royalty Pharma in a research note on Friday, February 27th. Wall Street Zen lowered Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Citigroup boosted their target price on Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Morgan Stanley upped their price target on Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a research report on Friday, April 10th. Finally, UBS Group raised Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 price target for the company in a research report on Friday, January 30th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $49.00.

Royalty Pharma Trading Up 3.1%

RPRX opened at $50.00 on Friday. The business has a 50 day simple moving average of $46.45 and a two-hundred day simple moving average of $41.56. The firm has a market capitalization of $28.84 billion, a price-to-earnings ratio of 37.04, a PEG ratio of 3.10 and a beta of 0.39. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.40 and a quick ratio of 2.40. Royalty Pharma PLC has a one year low of $31.58 and a one year high of $50.00.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.33 by $0.13. The business had revenue of $621.99 million during the quarter, compared to analyst estimates of $839.97 million. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%. Analysts predict that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $0.235 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a yield of 1.9%. Royalty Pharma’s dividend payout ratio is presently 69.63%.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.